| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 03/02/2004 | US6699877 Substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid derivatives |
| 03/02/2004 | US6699871 Such as 7-((3r)-3-amino-4-(3,4-difluorophenyl)butanoyl)-2-(trifluoromethyl)-5,6,7,8 -tetrahydroimidazo(1,2-a)pyrazine dihydrochloride for treatment of insulin resistance disorders |
| 03/02/2004 | US6699867 4-(4-Methyl-piperazin-1-ylmethyl)-4,5-dihydrothiazol-2-ylamine |
| 03/02/2004 | US6699865 Protein kinase inhibitors, for treating cancer inflammatory disorders, restenosis, and cardiovascular disease. |
| 03/02/2004 | US6699864 Substituted phenyl-piperazine derivatives, their preparation and use |
| 03/02/2004 | US6699860 Di-substituted aminomethyl-chroman derivative beta-3 adrenoreceptor agonists |
| 03/02/2004 | US6699859 Treatment of anxiety and convulsions. |
| 03/02/2004 | US6699858 Halogen substituted tetracyclic tetrahydrofuran derivatives |
| 03/02/2004 | US6699856 Pyrazinones, compositions containing such compounds and methods of use |
| 03/02/2004 | US6699852 Substituted pyridoindoles as serotonin agonists and antagonists |
| 03/02/2004 | US6699840 Controlled- or delayed-release forms of topiramate |
| 03/02/2004 | US6699837 Treatment of neurons with HGF |
| 03/02/2004 | US6699682 Assay for inhibitors of fatty-acid amide hydrolase |
| 03/02/2004 | US6699681 Identifying compounds that upregulate eces; regulating a beta catabolism in a cell and decreasing the amount of a beta in a cell; diagnosing and treating alzheimer's disease; mutant ece nucleic acids and mutant ece polypeptides. |
| 03/02/2004 | US6699660 Isolated nucleic acid identical to one expressed in response to seizure or ischemia |
| 03/02/2004 | US6699506 Pharmaceutical composition with extended release of Milnacipran |
| 03/02/2004 | US6699466 IL-16 antagonist peptides and DNA encoding the peptides |
| 03/02/2004 | CA2138289C N-substituted azabicycloheptane derivatives, the preparation and use thereof |
| 02/26/2004 | WO2004016769A2 Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof |
| 02/26/2004 | WO2004016621A1 C-substituted tricyclic isoxazoline derivatives and their use as anti-depressants |
| 02/26/2004 | WO2004016618A1 Oxycodone-hydrochloride polymorhs |
| 02/26/2004 | WO2004016617A1 Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists |
| 02/26/2004 | WO2004016616A1 Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists. |
| 02/26/2004 | WO2004016614A2 Pyrrolopyrazines as kinase inhibitors |
| 02/26/2004 | WO2004016613A2 Purine derivatives and their use as antiproliferative agents |
| 02/26/2004 | WO2004016612A2 New purine derivatives |
| 02/26/2004 | WO2004016608A1 Novel quinuclidine derivatives and their use |
| 02/26/2004 | WO2004016606A1 Pyrazole inhibitors of the transforming growth factor |
| 02/26/2004 | WO2004016605A1 2-aminopyrimidine derivatives as adenosine a1 and a2a receptor antagonists |
| 02/26/2004 | WO2004016597A2 Protein kinase inhibitors and uses thereof |
| 02/26/2004 | WO2004016593A1 Diaryl compounds as monoamine reuptake inhibitors |
| 02/26/2004 | WO2004016590A1 The salts of the quinuclidine derivatives and the preparation and applications thereof |
| 02/26/2004 | WO2004016583A1 Substituted glycine derivatives for use as medicaments |
| 02/26/2004 | WO2004016580A2 Derivatives of glycinergic r(+)-2-amino-3-hydroxypropanoic acid |
| 02/26/2004 | WO2004016578A2 Arylethanolamine beta2-adrenoreceptor agonist compounds |
| 02/26/2004 | WO2004016551A1 Method for the preparation of a silicic acid comprising extrudate, said extrudate, its use and a pharmaceutical composition comprising the said extrudate |
| 02/26/2004 | WO2004016287A1 Remedies for schizophrenia |
| 02/26/2004 | WO2004016282A1 Vaccine compositions containing amyloid beta1-6 antigen arrays |
| 02/26/2004 | WO2004016272A1 Use of reboxetine for the treatment of hot flashes |
| 02/26/2004 | WO2004016266A1 Methods of treating benzodiazepine site (bzd-s) associated syndromes using 2’ hydroxyflavonoids |
| 02/26/2004 | WO2004016265A1 Methods of predicting gabaa receptor efficacies for flavonoid compounds and uses therefor |
| 02/26/2004 | WO2004016260A1 Therapeutic use of fused bicyclic or tricyclic amino acids |
| 02/26/2004 | WO2004016259A1 Synergistic combination of an alpha-2-delta ligand and a pdev inhibitor for use in the treatment of pain |
| 02/26/2004 | WO2004016246A1 Cannabinoid liquid formulations for mucosal amdinistration |
| 02/26/2004 | WO2004016244A2 Pharmaceutical compositions for buccal delivery of pain relief medications |
| 02/26/2004 | WO2004016083A1 Nonhuman animal reproducing pathogenic conditions of spinal and bulbar muscular atrophy and remedy for spinal and bulbar muscular atrophy |
| 02/26/2004 | WO2004005336A3 β-SHEET BREAKING PEPTIDES |
| 02/26/2004 | WO2004000369A3 Method of magnetically manipulating a cell with magnetisable particles |
| 02/26/2004 | WO2004000237A3 Enhancing treatment of mdr cancer with adenosine a3 antagonists |
| 02/26/2004 | WO2003103584A3 Ether substituted imidazopyridines |
| 02/26/2004 | WO2003101374A3 Use of new etonogestrel esters |
| 02/26/2004 | WO2003099337A3 Inclusion complexes of rosiglitazone |
| 02/26/2004 | WO2003097564A3 Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof |
| 02/26/2004 | WO2003091387A9 Non-invasive delivery of polypeptides through the blood-brain barrier, and in vivo selection of endocytotic ligands |
| 02/26/2004 | WO2003088970A3 Modulators of hedgehog signaling pathways, compositions and uses related thereto |
| 02/26/2004 | WO2003087345A3 Stimulation of nerve cell regeneration |
| 02/26/2004 | WO2003087333A3 Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| 02/26/2004 | WO2003076398A3 Pyrrole-2, 5-dione derivatives and their use as gsk-3 inhibitors |
| 02/26/2004 | WO2003074008A3 Aminoalkylphosphonates and related compounds as edg receptor agonists |
| 02/26/2004 | WO2003064443A3 New corticosteroids |
| 02/26/2004 | WO2003060085A3 Mammalian neural stem cells, compositions and uses thereof |
| 02/26/2004 | WO2003057144A3 Change inhibitors of dipeptidyl peptidase iv |
| 02/26/2004 | WO2003046568A3 Protein biopolymer markers indicative of a disease state |
| 02/26/2004 | WO2003040144A3 Heterocyclic compound based on n6-substituted adenine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds |
| 02/26/2004 | WO2003032990A3 Polymer conjugates of opioid antagonists |
| 02/26/2004 | WO2003029495A3 Coniosulphides and their derivatives, method for their production and use as medicaments |
| 02/26/2004 | WO2003028543A3 Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease |
| 02/26/2004 | WO2003024434A3 Use of a superoxide dismutase mimetic catalyst in the manufacture of a medicament for preventing and treating hiv-mediated central nervous system damage |
| 02/26/2004 | WO2003013493A8 Histone deacetylase enzyme-inhibiting derivatives of hydroxamic acid as new cytokine synthesis-inhibiting anti-inflammatory drugs |
| 02/26/2004 | WO2003012137A3 Methods for detecting parkinson's disease |
| 02/26/2004 | WO2003011892A3 Glp-1 exendin-4 peptide analogs and uses thereof |
| 02/26/2004 | WO2002098869A3 1,4-disubstituted benzo-fused cycloalkyl urea compounds |
| 02/26/2004 | WO2002096351A3 Ultrashort-acting opioids for transdermal application |
| 02/26/2004 | WO2002083683A9 Novel tricyclic pyridyl benzazepine carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists |
| 02/26/2004 | WO2002083058A3 Anti-inflammatory fatty alcohols and fatty acid esters useful as antigen carriers |
| 02/26/2004 | WO2002066672A3 Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists |
| 02/26/2004 | WO2002057211A8 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (adp-ribose) glycohydrolase, and methods for their use |
| 02/26/2004 | WO2002055067A3 Fumaric acid derivatives as nf-kappab inhibitors |
| 02/26/2004 | WO2002046418A3 Lipid-associated molecules |
| 02/26/2004 | WO2002045496A3 Transenic mice containing frp-rs4 gene disruptions |
| 02/26/2004 | WO2002030902A8 Crystal forms of 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]piperazine.hydrochloride |
| 02/26/2004 | WO2002022112A3 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| 02/26/2004 | WO2001057175A3 Methods and materials relating to neurotrimin-like polypeptides and polynucleotides |
| 02/26/2004 | US20040039200 1,2,3,4,10,10a-hexahydropyrazino(1,2-a)indole derivatives useful for treating disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders, and diabetes |
| 02/26/2004 | US20040039198 Administering to a mammal an aromatic and heteroacromatic substituted imidazole compound to treat diseases: renal disease, wound healing, ucler, ocular disorder, diabetic nephropathy, atherosclerosis, fibrosis, ALzheimer's disease |
| 02/26/2004 | US20040039066 Administering hydroxytyrosol and oleuropein in a ratio of 1:1-200:1 |
| 02/26/2004 | US20040039065 Autonomic nerve regulating agent |
| 02/26/2004 | US20040039064 Treating and/or preventing alzheimer's disease and other neurodegenerative diseases; beta-secretase inhibitors |
| 02/26/2004 | US20040039058 Identifying a mammal having elevated concentrations of tumor necrosis factor- alpha and administering stearidonic acid (18:4, n-3) over a time period |
| 02/26/2004 | US20040039050 Formulating phenanthro(1,2-b)-furan compound for eliminating hyperammonemia in the brain tissue for treating early stage Alzheimer's disease |
| 02/26/2004 | US20040039046 Scyphostatin analogues as SMase inhibitors |
| 02/26/2004 | US20040039045 (2-azabicyclo(2.2.1)hept-7yl)methylcarbamate derivatives are useful for treating schizophrenia, Alzheimer's disease, neurodegenerative disorders, Parkinson's disease, Tourette's syndrome, age related memory loss and withdrawal symptoms |
| 02/26/2004 | US20040039044 Coupling under reducing conditions aminoalkylpyrrolidine-n-alkyl with one equivalant of a aldehyde compound; useful for treating pain, schizophrenia, depression and sleep disorders |
| 02/26/2004 | US20040039041 Using an alfa2-adrenoceptor antagonist or an ester or salt selected from atipamezole, idazoxan, efaroxan or their salts, to prevent dyskinesias caused by chronic use of dopaminergic agents while treting neuropsychiatric disorders |
| 02/26/2004 | US20040039038 Biaromatic compound activators of PPARy-type receptors |
| 02/26/2004 | US20040039034 Hydroxypropyl amides for the treatment of Alzheimer's disease |
| 02/26/2004 | US20040039029 Thiazolyl urea compounds and methods of uses |
| 02/26/2004 | US20040039025 Substituted hydrazine derivatives |
| 02/26/2004 | US20040039024 Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them |
| 02/26/2004 | US20040039023 Therapeutic agents |